Lamivudine/zidovudine (DrugBank: Zidovudine, Lamivudine)
7 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
25 | 進行性多巣性白質脳症 | 0 |
26 | HTLV-1関連脊髄症 | 0 |
94 | 原発性硬化性胆管炎 | 0 |
135 | アイカルディ症候群 | 0 |
265 | 脂肪萎縮症 | 1 |
325 | 遺伝性自己炎症疾患 | 0 |
331 | 特発性多中心性キャッスルマン病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00005764 (ClinicalTrials.gov) | May 2000 | 30/5/2000 | A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients | Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) | HIV Infections;Lipodystrophy | Drug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: Lamivudine | Glaxo Wellcome | NULL | Completed | 18 Years | N/A | Both | 100 | Phase 4 | United States |